Results
There were 8 women and 4 men with a mean age of 67.1 years (range 45-83 years). There were 4 coronary artery bypass grafting operations, 4 valvular operations, 3 combined coronary and valvular operations, and 1 ventricular assist device procedure (Table  1) . Before nesiritide infusion, the mean systolic blood pressure was 115 mm Hg, the mean systolic PAP was 63.5 mm Hg, the mean CVP was 22.5 mm Hg, and the mean CI was 1.7 L/(min · m 2 ). The mean baseline serum creatinine level was 1.3 g/dL. After the operation, the mean systolic blood pressure was 114 mm Hg, the mean systolic PAP was 40.1 mm Hg, the mean CVP was 14 mm Hg, and the mean CI was 2.5 L/(min · m 2 ) ( Table 2 ). The mean urinary output for the first 24 postoperative hours was 2290 mL. The mean postoperative serum creatinine level was 1.4 g/dL. The mean ventilator time, intensive care unit stay, and postoperative length of stay were 9.5 hours, 2.3 days, and 8 days, respectively. There were no deaths and 6 morbidities: 1 surgical hemorrhage requiring re-exploration, 2 cases of prolonged mechanical ventilation (Ͼ24 hours), and 3 new-onset atrial fibrillations. No patient required discontinuation of nesiritide before the establishment of an optimal hemodynamic state. Nesiritide infusion remained at 0.01 g/(kg · min) during the entire infusion period. The mean duration of nesiritide therapy was 35 hours (range 24-48 hours).
Discussion
Nesiritide, human recombinant B-type natriuretic peptide, is among a family of natriuretic peptides with vasodilatory effects. Its role in the treatment of decompensated congestive heart failure is well established. Hemodynamic efficacy with direct and indirect cardiovascular and renal responses has been demonstrated. 1 Nesiritide has been shown to directly augment coronary artery perfusion, 2 reduce pulmonary capillary wedge pressure, PAP, and CVP, and indirectly improve cardiac output with no effect on heart rate. 3 Nesiritide has also been shown to increase urinary sodium excretion (natriuresis) and urinary volume while preserving creatinine clearance. 4 Finally, nesiritide suppresses the release of norepinephrine, the release of endothelin 1, and the renin-angiotensinaldosterone axis. 5 The role of nesiritide in adult cardiac surgery is undefined. A limited number of studies have examined the use of nesiritide in various settings.
6-8 Truong and associates, 6 for example, described 24 patients requiring inotropic support (milrinone) who were evaluated for transplantation after a 24-to 48-hour nesiritide infusion. As a result of the improved hemodynamics, 14 patients were directly listed and 7 additional patients received elective-as opposed to emergency-left ventricular assist devices. Similarly, nesiritide therapy has been found to act favorably as an adjunct to the treatment of decompensated heart failure immediately after cardiac transplantation. 7 Finally , Moazami and colleagues 8 have described positive cardiovascular and renal effects in 2 patients given nesiritide after coronary artery bypass grafting. 8 Our study adds to the experience of others in helping to define the role of nesiritide in cardiac surgery. As the complexity of cardiac surgery becomes more apparent, with sicker patients and weaker hearts, advanced pharmacologic therapies become neces- sary for management. The properties of nesiritide lend themselves to the heart failure population, whether medical or surgical. In an effort to define nesiritide's role and application, we sought to establish a protocol in which a nesiritide infusion was instituted in patients with heart failure undergoing cardiac surgery. Specific parameters were defined in the operating room, and a simple infusion scheme was established. The infusion was kept constant until the desired hemodynamic status was achieved, often in combination with other cardiac medications (eg, milrinone). We found little role for loop diuretic and low-dose ("renal dose") dopamine. The use of norepinephrine was not uncommon, a consequence of the combined vasodilatory characteristics of milrinone and nesiritide. The duration of norepinephrine use was less than 48 hours and the dosage range was low. We did not observe any ventricular arrhythmias.
Conclusions
In our opinion, nesiritide therapy serves as an important adjunct in the management of patients with heart failure undergoing cardiac surgery. When combined with other cardiac medications, such as milrinone, a therapeutic balance of cardiovascular and renal effects is safe and practical. Transit-time flow measurement cannot detect wrong anastomosis of an internal thoracic artery with the cardiac vein in coronary artery surgery Yoshiyuki Takami, MD, and Hiroshi Masumoto, MD, Kasugai, Japan I n coronary artery surgery transit-time flow measurement is useful to determine graft patency and to detect graft failure intraoperatively. Previous reports have demonstrated the accuracy and reproducibility of this noninvasive and simple procedure. [1] [2] [3] [4] [5] In this report, however, we describe a case of wrong anastomosis of the left internal thoracic artery (LITA) with the cardiac vein, which could not be detected with transit flow measurement.
Clinical Summary
A 72-year-old man with effort angina was referred for coronary artery surgery. His coronary angiograms revealed occlusion of the distal right coronary artery and significant stenosis of the left main stem, the proximal left anterior descending artery, and the proximal left circumflex artery. He underwent triple coronary artery bypass grafting during cardiopulmonary bypass. The LITA was grafted to the left anterior descending artery, the left radial artery to the obtuse marginal branch of the left circumflex artery, and the saphenous vein to the atrioventricular branch of the right coronary artery. The result of transit-time flow measurement of the LITA graft is demonstrated in Figure 1 (Figure 1, B) , although both aorta-coronary grafts (radial artery and saphenous vein) were patent.
Discussion
In the transit-time method it is neither necessary to know the vessel diameter nor to perform any complex calibrating procedures. Therefore intraoperative transit-time flow measurement has become increasingly popular to check the anastomotic quality in coronary artery bypass grafting. 5 As we have already demonstrated in the quantitative angiographic evaluation, 2, 3 intraoperative Qm is closely related to the degree of the stenosis at the most stenotic portion of the anastomosis. However, we cannot completely rely on the Qm value to determine the anastomotic quality of the graft. It is possible to have a patent anastomosis with a low Qm because the optimal Qm varies with the dynamic character, including blood pressure, heart rate, coronary resistance, and graft diameter. 1, 5 We cannot necessarily judge a graft with a Qm of less than 20 mL/min as nonpatent in the operating room. In contrast, surgeons can consider a graft with a Qm of greater than 20 mL/min as patent. 1 In addition, on the basis of the specific physiology of coronary circulation, patent graft flow is predominantly diastolic, forming a trapezoid-shaped waveform with a short systolic peak, as demonstrated in Figure 2 . On the contrary, there is no diastolic flow in an occluded graft. [2] [3] [4] In the patient in this report, the intraoperative Qm of the LITA was 48 mL/min, and its flow pattern was diastolic dominant. We considered the LITA as patent in the operating room. However, the postoperative angiogram revealed that the LITA had been accidentally anastomosed with the cardiac vein and not with the left coronary artery that we had intended to use for anastomosis. The arteriovenous flow pattern is similar to the arterioarterial flow pattern in coronary circulation. Although it is uncommon to perform incorrect grafting of the LITA to the cardiac vein, we should know that the transit-time flow measurement cannot differentiate the wrong anastomosis.
